NCT07226843 2026-04-17
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Eli Lilly and Company
Phase 1 Not yet recruiting
Clinical Trials
15 trialsNCT07519772 2026-04-09
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Merck Sharp & Dohme LLC
Phase 1/2 Not yet recruiting
NCT07422610 2026-04-02
Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment
Novartis
Phase 1 Not yet recruiting
NCT07101328 2026-03-20
BAF_FRontier-1
Eli Lilly and Company
Phase 1 Not yet recruiting
NCT07282548 2026-03-02
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies
Ipsen
Not yet recruiting
NCT07424833 2026-02-20
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Ascentage Pharma Group Inc.
Phase 1 Not yet recruiting
NCT07360288 2026-01-22
TC011_FL_201
TICAROS Co., Ltd.
Phase 2 Not yet recruiting
NCT06985576 2025-12-18
Long-term Study to Evaluate Safety and Persistence of GF-CART01
GenomeFrontier Therapeutics TW Co., Ltd.
Not yet recruiting
NCT07187960 2025-09-23
Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Not yet recruiting
NCT07092852 2025-07-30
PGx Medication Safety Reviews of Persons With IDD
GalenusRx, Inc.
Not yet recruiting
NCT07011966 2025-06-10
ASV Therapy for Insomnia
ResMed
Phase NA Not yet recruiting
NCT06368167 2024-04-16
A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Not yet recruiting
NCT06142188 2023-11-21
Relmacabtagene Autoleucel in Hematologic Malignancies
Shanghai Ming Ju Biotechnology Co., Ltd.
Not yet recruiting
NCT06049485 2023-09-22
Assessing the Experience of Patients Undergoing Follicular Lymphoma Clinical Research
Power Life Sciences Inc.
Not yet recruiting
NCT02194751 2021-04-08
Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma
XEME Biopharma Inc.
Phase 2 Not yet recruiting